Asset profile

mirikizumab · Omvoh

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (5)
May 2027 (1)
Phase 2Ulcerative ColitisRecruiting
Est. primary completion 2027-05 · NCT07186101 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)
Phase 2Crohn DiseaseRecruiting
Est. primary completion 2027-06 · NCT07483099 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Ulcerative ColitisRecruiting
Est. primary completion 2027-06 · NCT07483073 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 2Ulcerative ColitisRecruiting
Est. primary completion 2027-12 · NCT06598943 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-12 · NCT05509777 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
April 2028 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 3Crohn's Disease, Obesity or OverweightRecruiting
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
December 2030 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2030-12 · NCT04844606 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.